GNAS and neoplasm: Given the activated IFN signature observed in the combined GNAS KO plus RGFP966 condition and the critical role of IFN signaling in anti-tumor immune responses, we explored whether GNAS KO can synergize with HDAC3 inhibition to promote anti-tumor immunity such as CD8+ T cell-induced cytotoxicity.